Its FDA labeling describes it as a sympathomimetic amine anorectic indicated as a short-term the label says "a few weeks" adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction, for the management of exogenous obesity in patients with an initial body mass index of 30 kg/m or greater, or 27 kg/m or greater in the presence of other risk factors such as controlled hypertension, diabetes, or hyperlipidemia
Conflict of interest Authors have no conflict of Interest
There are exciting new options for those living with obesity and at higher risk of developing diabetes, but it is critical we support these individuals in a comprehensive manner and with a highly personalized and clinically appropriate treatment plan
Davidson, M
For example, Cognizin has been the subject of several studies to improve cognitive impairment, including one in which 500mg/day resulted in improvements on numerous memory tests over placebo.5 In another study, 500mg and 2,000mg of Cognizin improved brain ATP levels and increased the speed of brain membrane formation.103 The closest thing to this currently on the market is Revive Brain+, which recently reformulated to include PQQ and branded Cognizin citicoline
